Disodium pamidronate

Bezeichnung:Disodium pamidronate

CAS-Nr109552-15-0

Englisch Name:Disodium pamidronate

CBNumberCB7707410

SummenformelC3H14NNaO8P2

Molgewicht277.08

MOL-Datei109552-15-0.mol

Disodium pamidronate physikalisch-chemischer Eigenschaften

storage temp.	2-8°C
Löslichkeit	Soluble in water, practically insoluble in methylene chloride. It is sparingly soluble in dilute mineral acids and dissolves in dilute alkaline solutions.
Aggregatzustand	White solid
Farbe	White to off-white
Wasserlöslichkeit	water: 10mg/mL
CAS Datenbank	109552-15-0(CAS DataBase Reference)

Sicherheit

WGK Germany	3
RTECS-Nr.	SZ6522666
HS Code	2931909042
Toxizität	women,TDLo,intravenous,1200ug/kg (1.2mg/kg),BEHAVIORAL: ATAXIAMUSCULOSKELETAL: OTHER CHANGES,Australian and New Zealand Journal of Medicine. Vol. 27, Pg. 719, 1997.

Gefahreninformationscode (GHS)

Disodium pamidronate Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
White or almost white, crystalline powder.
Originator
Aredia,Novartis,India
Verwenden
Pamidronate Disodium Salt Pentahydrate is a calcium metabolism regulator.
Verwenden
Bone resorption inhibitor.
Definition
ChEBI: Pamidronate disodium is a 1,1-bis(phosphonic acid).
Manufacturing Process
For a batch size of 5 L, 587.5 g (3.2 moles) of mannitol is dissolved in 3.5 L of water. Pamidronic acid (31.6 g, 0.133 moles) is mixed with a 1.0 L aliquot of the mannitol solution to form a slurry. The slurry is then transferred into the remainder of the mannitol solution, and stirred for at least 15 min. Aqueous 1 N sodium hydroxide (270 ml) is then added and the mixture is stirred until a clear, colorless solution results. The pH is then adjusted to 6.50.1 using either 1 M aqueous phosphoric acid or 1 N aqueous sodium hydroxide, as needed. The solution is then filtered through a 0.22 micron filter, and filled at 20°C into vials at 4.0 ml (4.172 g)/vial, under sterile conditions. The aqueous solution is frozen at -37°C and lyophilized (20 mbar, 20°-40°C) to yield 1,250 vials, each containing 30 mg of amorphous disodium pamidronate. The vials are sealed under positive nitrogen pressure. The disodium pamidronate is amorphous (noncrystalline) by X-ray diffraction and contains 0.7 wt-% water.
Trademarks
Aredia (Novartis).
Therapeutic Function
Bone resorption suppressant
Biologische Aktivität
Cell permeable: no', 'Primary Target
Inhibitor of bone resorption', 'Product does not compete with ATP.', 'Reversible: no
Clinical Use
Pamidronate, a second-generation bisphosphonate, is 100-fold more potent than etidronate. It has been approved for the treatment of hypercalcemia of malignancy, for Paget's disease, and for osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. When used to treat bone metastases, pamidronate decreases osteoclast recruitment, decreases osteoclast activity and increases osteoclast apoptosis. Erosive esophagitis has been reported with the use of pamidronate sodium.
Stoffwechsel
Pamidronate is not metabolised, and about 20-55% of the dose is excreted in the urine unchanged within 72 hours; the remainder is mainly sequestered to bone and only very slowly eliminated.

Disodium pamidronate Upstream-Materialien And Downstream Produkte

Disodium pamidronate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

109552-15-0, Disodium pamidronate Verwandte Suche:

Send Inquriy